GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back
Pandemic Will Continue To Affect Shingles Vaccine
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.
You may also be interested in...
Pfizer’s earnings were skewed by its coronavirus vaccine for the second quarter running while GSK’s vaccine sales were helped by the catch-up on pediatric immunization schedules. Sales of influenza vaccines may come to the fore in the second half.
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.
AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.